Short answer
Amneal Pharmaceuticals, Inc. (AMRX) filed an 8-K current report with the SEC on February 27, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure). Q4 and full-year 2025 earnings released Feb 27, 2026; results cover period ended December 31, 2025.
Amneal Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q4 and full-year 2025 earnings released Feb 27, 2026; results cover period ended December 31, 2025
- Full financials in Exhibit 99.1 press release: key figures not disclosed in this filing item
Item 7.01 · Regulation FD Disclosure
- Amneal hosting earnings call Feb 27, 2026 at 8:30am ET to discuss quarterly/annual results
- Webcast accessible at investors.amneal.com; dial-in (833) 470-1428, access code 937407
- Replay available post-call for investors unable to attend live
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Amneal Pharmaceuticals, Inc. 8-K filings
Get the next AMRX 8-K as it lands
Follow AMRX for push alerts, or ask the research agent what this filing means.